As KNOX News Radio, Local News, Weather and Sports reported, the Food and Drug Administration announced a new warning for GLP-1 drugs regarding permanent vision loss risk. The condition, identified as the eye condition non-arteritic anterior ischemic optic neuropathy, causes decreased optic nerve blood flow.
Food and Drug Administration scientists investigated the matter after a two thousand twenty-four medical paper on semaglutide prompted a closer look. According to the American Academy of Ophthalmology, this eye condition affects two to ten of every one hundred thousand adults over age fifty. Furthermore, an Food and Drug Administration analysis of over one hundred twenty-five clinical trials found that six per one hundred thousand individuals were affected.
Major pharmaceutical companies involved with these medications have responded to the federal update. Novo Nordisk stated that data does not establish a cause-and-effect relationship. Novo Nordisk told KNOX News Radio, Local News, Weather and Sports that the company "continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines."
Dr. Joseph Rizzo told KNOX News Radio, Local News, Weather and Sports that "The medicines have really been profoundly beneficial to a large number of people."
Additionally, Eli Lilly reported its own position on the matter. Eli Lilly stated that the company is carefully evaluating the update and will respond promptly.